AIM

SEC Filing Summary: Hemispherx Biopharma, Inc. (10-Q)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2008, for Hemispherx Biopharma, Inc., a biopharmaceutical company focused on immune system-enhancing therapies. The company's primary strategic focus is the clinical development of Ampligen (for Chronic Fatigue Syndrome and as a vaccine adjuvant) and the commercialization of Alferon N Injection (for genital warts). As of June 30, 2008, the company had an accumulated deficit of approximately $191.2 million.

Key Financial Metrics

Note: The company had no long-term debt as of June 30, 2008, having paid off convertible debentures in June 2007.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues dropped significantly from $234,000 in Q2 2007 to $15,000 in Q2 2008. This was primarily due to the cessation of Alferon N Injection sales in April 2008 after finished goods inventory expired in March 2008. Product sales revenue was $0 in Q2 2008 compared to $196,000 in Q2 2007.
• Reduced Net Loss: Net loss decreased by 29% in Q2 2008 ($2.8M) compared to Q2 2007 ($3.9M). This improvement was driven by a 54% reduction in R&D expenses ($1.4M decrease) as the company completed the filing of the Ampligen New Drug Application (NDA) in late 2007.
• Increased G&A Expenses: General and administrative expenses increased by 16% ($247,000) in Q2 2008, largely due to a $242,000 write-down of an intangible asset (a repurchased royalty) deemed to have insufficient inventory to realize its value.
• Investment Maturity: Short-term investments of $3.9 million held at year-end 2007 matured during the first half of 2008, resulting in a cash balance of $10.1 million and no short-term investments at June 30, 2008.

Guidance, Outlook, and Risks

• Regulatory Milestone: On July 7, 2008 (subsequent to the period end), the FDA accepted the company's amended NDA for Ampligen to treat Chronic Fatigue Syndrome for review. Approval would provide the first-ever treatment for this condition.
• Financing: On July 2, 2008, the company entered into a $30 million Common Stock Purchase Agreement with Fusion Capital Fund II, LLC. The company can sell shares up to this limit over 25 months, with pricing based on prevailing market rates. This agreement includes a commitment fee of 650,000 shares issued immediately.
• Alferon N Status: Commercial sales of Alferon N are halted due to expired inventory. The company is petitioning the FDA for an extension of the expiration date. If denied, production must resume, which is currently on hold to prioritize the Ampligen FDA pre-approval inspection. New product may not be available until late 2009 or early 2010.
• Liquidity: Management anticipates that current cash resources ($10.1 million) are sufficient to meet operating requirements for approximately 12 months.
• Risks: Key risks include the failure to obtain FDA approval for Ampligen, the inability to extend the expiration date of Alferon N inventory, potential dilution from the Fusion Capital agreement, and the need for additional capital if product commercialization is delayed.

Investor Verification Checklist

• Alferon N Inventory: Verify the status of the FDA petition to extend the expiration date of the Alferon N finished goods inventory and the timeline for resuming production.
• Ampligen NDA Review: Monitor FDA communications regarding the review of the Ampligen NDA for Chronic Fatigue Syndrome, specifically any requests for additional data or clinical trials.
• Financing Execution: Track the utilization of the $30 million purchase agreement with Fusion Capital and the associated share issuance to assess dilution impact.
• Cash Burn Rate: Confirm the company's ability to maintain operations for the projected 12-month runway given the lack of significant product revenue.
• Legal Settlements: Review the finalization of legal settlements with Bioclones and Laboratorios del Dr. Esteve mentioned in the subsequent events section.